Pheochromocytoma - Pipeline Review, H1 2018

  • ID: 4518503
  • Drug Pipelines
  • 99 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Exelixis Inc
  • Ipsen SA
  • Novartis AG
  • Pfizer Inc
  • Tarveda Therapeutics Inc
  • MORE
Pheochromocytoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Pipeline Review, H1 2018, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.

Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL) and neurofibromatosis 1 (NF1).

Report Highlights:

This latest pipeline guide Pheochromocytoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pheochromocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pheochromocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 1, 7 and 2 respectively.

Pheochromocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pheochromocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pheochromocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pheochromocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pheochromocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pheochromocytoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pheochromocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pheochromocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Exelixis Inc
  • Ipsen SA
  • Novartis AG
  • Pfizer Inc
  • Tarveda Therapeutics Inc
  • MORE
Introduction

Report Coverage

Pheochromocytoma - Overview

Pheochromocytoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pheochromocytoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pheochromocytoma - Companies Involved in Therapeutics Development

Exelixis Inc

Ipsen SA

Lixte Biotechnology Holdings Inc

Novartis AG

Pfizer Inc

Progenics Pharmaceuticals Inc

Tarveda Therapeutics Inc

Valeant Pharmaceuticals International Inc

Pheochromocytoma - Drug Profiles

177Lu-Satoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iobenguane I 131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LMP-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lutetium Lu 177 dotatate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metyrosine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONC-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEN-221 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pheochromocytoma - Dormant Projects

Pheochromocytoma - Product Development Milestones

Featured News & Press Releases

Mar 22, 2018: Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA (iobenguane I 131)

Mar 19, 2018: Progenics Pharmaceuticals Announces Presentation of AZEDRA (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society Annual Meeting

Feb 01, 2018: Progenics Pharmaceuticals Announces Presentation of AZEDRA (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

Dec 29, 2017: Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Nov 02, 2017: Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA (iobenguane I 131) in Pheochromocytoma and Paraganglioma

Oct 04, 2017: Data from Pivotal Phase 2b Study of Progenics’ AZEDRA (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium

Aug 31, 2017: Progenics Pharmaceuticals Presents Data from AZEDRA Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma

Aug 31, 2017: Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA

Mar 30, 2017: Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of AZEDRA

Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA

Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra

Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2

Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2

Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pheochromocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pheochromocytoma - Pipeline by Exelixis Inc, H1 2018

Pheochromocytoma - Pipeline by Ipsen SA, H1 2018

Pheochromocytoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018

Pheochromocytoma - Pipeline by Novartis AG, H1 2018

Pheochromocytoma - Pipeline by Pfizer Inc, H1 2018

Pheochromocytoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2018

Pheochromocytoma - Pipeline by Tarveda Therapeutics Inc, H1 2018

Pheochromocytoma - Pipeline by Valeant Pharmaceuticals International Inc, H1 2018

Pheochromocytoma - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Pheochromocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Exelixis Inc
  • Ipsen SA
  • Lixte Biotechnology Holdings Inc
  • Novartis AG
  • Pfizer Inc
  • Progenics Pharmaceuticals Inc
  • Tarveda Therapeutics Inc
  • Valeant Pharmaceuticals International Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll